Articles tagged with Colorectal Cancer
Researchers at UC Irvine have developed a 3D human colon model integrated with bioelectronics to aid in colorectal cancer research and drug discovery. The model shows promising results in detecting resistance to chemotherapy drugs, making it a potential alternative to traditional animal testing.
Researchers at UT Austin have developed a new cancer treatment that uses LED light and SnOx nanoflakes to precisely target cancer cells without harming healthy ones. The treatment achieved remarkable effectiveness in neutralizing colorectal and skin cancer cells, with up to 92% kill rate in just 30 minutes of exposure.
Researchers at UCSF have discovered a novel combination of immunotherapies that can reprogram the immune environment of colon cancer tumors in the liver. This therapy often eliminated tumors entirely in preclinical models, showing promise for treating patients with advanced colorectal cancer.
Researchers found microplastic exposure changes the human gut microbiome, with some shifts resembling patterns linked to diseases. Microplastic-induced changes in microbial composition may serve as a bacterial stress response, potentially affecting overall well-being.
Researchers found that rectal bleeding increases the odds of a colorectal cancer diagnosis by 8.5 times in patients under 50, highlighting the need for symptom-driven care and lifestyle modifications to reduce the risk. The study analyzed 443 patients and identified no family history as a factor in early-onset colorectal cancers.
A California court has ruled that processed meat, classified as a carcinogen by the World Health Organization, should not be included on the state's Proposition 65 list. This decision endangers public health and increases colorectal cancer risk, particularly among younger people.
The University of Cincinnati Cancer Center is conducting a study on combining KRAS inhibitors with HER3 targeted agents to treat colorectal cancers. The goal is to extend patient lives and reduce toxic treatments. Researchers hope to develop new, less-toxic options for patients whose cancer has spread.
Researchers at Mayo Clinic identified a genetic factor contributing to severe liver damage after chemotherapy for colorectal cancer patients. A specific gene variant, PNPLA3, was linked to increased risk of liver injury.
A new study published in Diabetes, Obesity and Metabolism found that weight loss treatments, including medication and surgical procedures, may help lower the risk of obesity-related cancers in people with obesity and type 2 diabetes. The study analyzed data from over 180,000 people and found a significant reduction in cancer incidence ...
A 71-year-old man was diagnosed with advanced colorectal cancer after suffering from multiple unexplained strokes and blood clots. The cancer remained undetected until widespread clot complications appeared, highlighting the need for comprehensive oncologic evaluation in patients with unexplained hypercoagulable states.
Researchers developed an engineered strain of gut-homing bacteria that induces mature tertiary lymphoid structures, associated with improved survival and stronger treatment responses. The therapy also restored healthy gut microbiota and showed excellent biocompatibility.
A new study found that sugary drinks can fuel metastasis in preclinical models of advanced colorectal cancer by activating an enzyme called sorbitol dehydrogenase. This pathway is also targeted by statins, common heart drugs. Reducing sugary drink consumption and targeting this enzyme may offer opportunities to reduce metastasis.
A blood test using microbial DNA analysis can distinguish primary liver cancer from colorectal cancer that has spread to the liver, according to a new study. The test reveals distinct bacterial 'fingerprints' for each cancer type, making it a powerful tool for non-invasive diagnosis and potential future therapy guidance.
Armida Labs will use the funding to advance preclinical studies of Targefrin, a potential clinical candidate for pancreatic and other cancers. The grant aims to develop an anti-metastatic agent that targets the EphA2 protein, which drives cancer cell invasion and metastasis.
A randomized clinical trial shows that low-dose aspirin reduces the risk of recurrence by 55% in patients with colon and rectal cancer harboring a specific genetic mutation. Aspirin's anti-inflammatory and anti-tumor effects may be responsible for its therapeutic benefits.
The Alliance for Clinical Trials in Oncology will host a public webinar showcasing key findings from the 2025 ASCO Annual Meeting. Researchers will discuss latest information on colorectal, squamous cell, and renal cell cancers.
A new study found that providing personalized colorectal cancer risk information to patients and their health care providers did not improve screening rates for the deadly ailment. Colorectal cancer is the second-most common cause of death from cancer in the United States, claiming nearly 55,000 lives annually.
Researchers found that colorectal cancer cells stimulate cancer-associated fibroblasts to produce collagen through TGF-β1-induced de novo glycine synthesis. PHGDH is identified as a potential therapeutic target for treating colorectal cancer.
Researchers at MD Anderson have made significant advancements in treating kidney cancer, including the use of metastasis-directed targeted radiation therapy to delay systemic treatments. Additionally, preliminary data from an ELI-002 vaccine trial showed promise in delaying relapse of KRAS-mutated pancreatic and colorectal cancers.
A large-scale study found that genetic variants and ancestry play a significant role in colorectal cancer risk in Brazil. The study identified nine genetic variants associated with disease risk, including four that contributed to the risk independently of other factors.
Researchers found a unique microbial signature in colorectal cancer samples that can accurately distinguish them from other types of cancer. This discovery has the potential to improve diagnosis and treatment outcomes for patients with colorectal cancer.
A randomized controlled trial found that personalized risk messages failed to increase colorectal cancer screening participation. Despite the lack of improvement, researchers emphasize the importance of continued research and potential improvements for uptake, effectiveness, and efficiency of CRC screening.
The foundation provides $300,000 total funding over four years to investigate cancer causes, mechanisms, therapies, and prevention. This support fosters interdisciplinary research and encourages innovative projects that push boundaries and make breakthroughs.
Recent advancements in screening methods and point-of-care diagnostics offer hope for early detection and improved outcomes in colorectal cancer. Emerging technologies such as single-cell sequencing, spatial transcriptomics, and artificial intelligence are being leveraged to enhance diagnostic accuracy and personalized risk prediction.
Researchers found that patients carrying colibactin-producing Escherichia coli in their colon polyps were more than three times as likely to have a history of colorectal cancer compared to those without the bacterium. The study suggests that targeting specific microbes could help prevent cancer in high-risk groups.
A novel AI model developed by the Dresden research team simultaneously detects multiple genetic alterations directly from routinely stained histological colon cancer tissue sections. The model recognized shared visual patterns rather than independently identifying individual genetic alterations.
A new study found a strong association between accelerated epigenetic aging and increased risk of colorectal cancer in postmenopausal women. Lifestyle factors like diet significantly influenced this risk, with healthy diets potentially reducing cancer risk associated with biological aging.
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
A nationwide Swedish study found nearly three times as many young adults under 50 diagnosed with colorectal cancer today compared to the early 1990s. The disease has become two to three times more common in this age group, with underlying causes not fully understood.
A study published in The Lancet Gastroenterology & Hepatology found that routine AI assistance during colonoscopies can lead to a decrease in the ability of endoscopists to detect precancerous growths without AI aid. This reduction in skills may impact patient-related outcomes and highlight the need for further research on the long-ter...
A novel cancer vaccine has shown encouraging early results in patients with pancreatic and colorectal cancer, two of the most difficult-to-treat malignancies. The vaccine targets KRAS mutations found in about 25% of solid tumors and drives about 90% of pancreatic cancers and 50% of colorectal cancers.
Researchers found people with both types of polyps are up to five times more likely to develop advanced pre-cancerous changes. The study supports growing evidence that these two types may represent separate cancer pathways.
A new deep learning model, MSI-SEER, achieves high accuracy in predicting microsatellite instability-high tumors and their responsiveness to immunotherapy. The model combines tumor MSI status with stroma-to-tumor ratio for highly accurate ICI response prediction.
A new study by the Germans Trias i Pujol Research Institute expands and optimizes 3D models to investigate colorectal cancer. The results show that different culture conditions affect spheroid morphology and compactness, highlighting the need for standardization.
Researchers found that automatically mailing a stool-based screening test resulted in the highest screening rates among adults aged 45-49. The study, which included over 20,000 patients, showed that this approach can encourage timely screening and potentially save lives.
Local-stage colorectal cancer incidence among US adults ages 45-49 increased by 50% between 2021 and 2022, with a steep rise in 2019-2022. Screening rates also increased during this period, driven by recommendations to start screening at age 45.
A UCLA-led study found that while blood-based tests offer a convenient option for screening, only 49% of patients completed a follow-up colonoscopy within six months. The study's findings highlight the need for improved follow-up care to detect and treat colorectal cancer effectively.
A new review integrates advances from genomics, transcriptomics, epigenomics, proteomics, metabolomics, and microbiomics to understand colorectal cancer's progression to the liver. The study identifies potential biomarkers and therapeutic targets, offering fresh hope for improving diagnosis and treatment outcomes.
Colorectal cancer claims more lives in Black communities than any other racial group, with incidence and mortality rates about 20% and 30% higher respectively. A new review by UCLA researchers highlights the need for equal access to screening, diagnosis, and treatment to eliminate these disparities.
Researchers discovered that statins selectively modulate key components of the Wnt/β-catenin signaling pathway, leading to lower levels of tumor-promoting proteins and cancer-suppressing cellular behaviors. Statins downregulate SATB1 while increasing SATB2, making cancer cells less able to grow and spread.
A recent national study reveals complex patterns of burden and survival trends for digestive system malignancies (DSMTs) in China. Despite progress in reducing mortality from some cancers, the overall impact remains significant, with notable disparities across demographic and geographic lines.
A new study published in JAMA Network Open found no statistical relationship between pathologic complete response (pCR) and overall survival in rectal cancer patients. This challenges the FDA's use of pCR as a surrogate endpoint for drug approval, which may lead to treatments being fast-tracked without evidence of improved long-term su...
Early-onset gastrointestinal cancers are rising globally, particularly among younger adults. Colorectal cancer is the most common early-onset GI cancer, accounting for over half of cases, and its incidence is increasing faster than any other type of early-onset cancer.
A recent analysis of 16 years of data on Japanese adults reveals a strong association between socioeconomic status and the incidence of five common cancers. Communities with low employment rates or low incomes show higher cancer rates compared to those with higher socioeconomic status.
The study highlights a significant increase in early-onset colorectal cancer rates globally, particularly in high-income countries. Younger patients are more likely to receive aggressive treatment without survival advantage, and survivors often report problems with anxiety, body image, and sexual dysfunction.
Researchers at UChicago have developed a more sensitive liquid biopsy test that uses RNA to detect the earliest stages of colorectal cancer with 95% accuracy. The test analyzes RNA modification levels in blood samples, which remain stable regardless of sample preparation.
A new study by Mass General Brigham found that hospitals that implemented improved recovery protocols saw a significant decrease in patients' long-term opioid use. The research suggests that minimizing opioid exposure during and after surgery can help reduce the risk of addiction.
Researchers at MD Anderson have made significant breakthroughs in cancer treatment, including improved outcomes for elderly patients with IDH-mutant AML who are not eligible for intensive chemotherapy. Additionally, new targeted therapies have been approved as frontline treatments, while pre-surgical radiation therapy may offer an alte...
Sylvester researchers found that alcohol-related cancer deaths increased by nearly double from 1990 to 2021, primarily affecting men over 55. A new four-drug combination has been shown to be highly effective and safe in treating patients with newly diagnosed multiple myeloma.
Researchers have identified a specific KRAS mutation, KRAS G12V, that may be targeted therapeutically to treat colon cancer. This mutation can be selectively inhibited using ACSS2 enzyme, potentially creating new therapeutic targets for personalized medicine.
A new precision oncology paper presents a case of a 62-year-old man with metastatic colorectal cancer who underwent multiple lines of therapy. The WIN International Molecular Tumor Board proposed personalized treatment plans based on the tumor's unique genetic mutations, highlighting the growing role of precision oncology in guiding th...
CIK cell therapy improved overall and progression-free survival for patients with colorectal cancer, regardless of disease stage. Serum CEA levels can predict treatment response, paving the way for a simple blood test.
This article highlights the regulatory effects of copper metabolism on cuproptosis in intestinal diseases like colitis and carcinogenesis. Cuproptosis exhibits a bidirectional regulatory role in modulating oxidative stress responses, metabolic reprogramming, and immunotherapeutic efficacy.
Researchers found that combining selinexor with Irinotecan shrunk tumors in preclinical models of colorectal cancer, suggesting a new potential treatment. The study also identified XPO1 mutations linked to rare cancers like endometrial cancer and found that these mutations make cells resistant to chemotherapy.
Patients with metastatic colorectal cancer treated with biweekly TAS-102 showed similar treatment effectiveness while experiencing reduced toxicity and lower rates of myelosuppression compared to standard dosing. This alternative schedule may be particularly useful for older patients or those with chemotherapy-related toxicities.
A University of British Columbia-led study found that colorectal cancer survivors experience a range of long-term sexual health issues, including dyspareunia and pelvic inflammatory disease. The study highlights the need for better education and support for women after cancer.
A circulating tumor DNA-based blood test demonstrated acceptable accuracy for colorectal cancer detection in an average-risk population. However, it struggled to detect advanced precancerous lesions, highlighting the need for further improvements.
A Phase III trial led by MD Anderson Cancer Center demonstrates a triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improves progression-free survival and overall survival in BRAF V600E-mutated metastatic colorectal cancer. The regimen offers a clear survival advantage over standard chemotherapy alone.
A new study analyzed trends over time in alcohol-linked cancer mortality across the US, finding nearly double the number of alcohol-related cancer deaths between 1990 and 2021. The burden is highest among men over 55, with liver, colorectal, and esophageal cancers seeing significant increases.
Researchers discovered biomarkers in gut bacteria and metabolites that can help diagnose and treat gastrointestinal diseases. The study found that certain biomarkers could predict multiple diseases, including gastric cancer and inflammatory bowel disease.